Arie Michelsohn
Posts by Arie Michelsohn
Reflections on Drug Patents and the High Cost of Healthcare
The Hatch-Waxman Act and the Biologic Price Competition and Innovation Act are both forged from a noble ideal, grounded in a commitment to a robust and earnest …
Drug Patents and the High Cost of Healthcare: Case of Over-Advocacy for Under-Patentability
The price-tag for non-innovative drug patents, such as these second-wave Restasis patents, is substantial. Indeed, one cannot help but question Allergan’s true motivations for attempting to …
The Abuse of Orange Book Listings by Branded Pharmaceutical Companies
AbbVie’s maneuver worked like clockwork to induce regulatory gridlock, which prevented generic competition and kept the company’s profits high at public expense, for years. Fortunately, …
Drug-Patent Abuse and the High Cost of Healthcare: Case of the Double-Half Dose-Time Injection
Ever since the Supreme Court decided KSR v. Teleflex, it has been appropriate to reject a patent claim because it was obvious to try. If twice the …
To Make Healthcare More Affordable, Fight Drug Patent Abuse with a Fury
If a drug company plants a more than 100-patent thicket to protect market exclusivity, then it had better be able to justify why it should deserve the …